Remove Leads Remove Safety Remove Side effects
article thumbnail

The debate on DTC marketing is going to heat up again

World of DTC Marketing

DTC ads do NOT lead to unnecessary Rxs. 3hree: DTC marketing minimizes the side effects of prescription drugs – One of the top pages within prescription drug websites continues to be “safety information.” 4our: DTC marketing should be illegal because it leads to unnecessary Rx’s.

Marketing 285
article thumbnail

Leading speciality pharmacies in pharma

Pharmaceutical Technology

Speciality pharmacies play a crucial role in medication dosing, disease and side effects management, and patient care. Patient education and medication adverse effect counselling. Patient monitoring for safety and efficacy. The post Leading speciality pharmacies in pharma appeared first on Pharmaceutical Technology.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Novel anti-epileptic drug demonstrates efficacy

European Pharmaceutical Review

A new approach to potassium-channel openers for epilepsy Critically, XEN1101 combines the effectiveness of potassium-channel openers with the safety of more traditional drugs, stated study lead author and neurologist Dr Jacqueline French. After a year or more, about 11 percent had no seizures.

article thumbnail

mRNA therapy could provide intracellular protein replacement for rare disease

European Pharmaceutical Review

For people with [propionic acidaemia], harmful amounts of toxic metabolites can build up in the body and lead to metabolic decompensation events and multisystemic complications. I am particularly proud of these results given that there are currently no therapeutic treatments approved for patients with this disease,” Dr Holen explained.

article thumbnail

First real-world study reveals encouraging efficacy for cell therapy

European Pharmaceutical Review

New results from a first-of-its-kind study reports that a CAR-T cell therapy provided similar efficacy and safety to relapsed or refractory multiple myeloma patients administered with the treatment in clinical trials.

article thumbnail

BMS strikes $14bn deal for Karuna Therapeutics

European Pharmaceutical Review

The deal includes Karuna’s lead asset KarXT (xanomeline-trospium), a potential first-in-class treatment for schizophrenia. KarXT targets both the M1 and M4 muscarinic receptors, resulting in a differentiated safety and efficacy profile.

article thumbnail

New Nkarta data backs up natural killer approach to cancer treatment

pharmaphorum

One leading proponent of the approach – South San Francisco’s Nkarta – has just reported new results from an early-stage trial of one of its CAR-NK therapies that will likely add to the enthusiasm for the field. There are still questions about the durability of the effects however, as NK cells have a limited lifespan within the body.